Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 1744 CL on QT/QTc Interval in Healthy Volunteers
NCT02172144Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in the mean time-matched QTcI. Started Jun 2007; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02172144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172144.